Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform General Information
Description
Rights of an allogeneic, non-viral chimeric antigen receptor (CAR) technology platform. Non-viral chimeric antigen receptor (CAR) technology platform which leverages Cytokine-Induced Killer (C.I.K.) cells as immune effector cells, is developed at University of Milano-Bicocca.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Healthcare Technology Systems
Acquirer
Primary Office
- Piazza dell'Ateneo Nuovo, 1
- 20126 Milan
- Italy
Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|